|Articles|October 28, 2020
In vitro glycoengineering – Suitability for BioPharma manufacturing
Author(s)Roche
Glycosylation homogeneity and pattern can be increase with cell line engineering and bioprocess optimization. But, these can be time-consuming and might compromise yield. In vitro glycoengineering can solve these problems and is independent from the cell line and the bioprocess used.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
How FDA’s Bayesian Guidance Could Accelerate Adaptive Trial Design in Biopharmaceuticals
2
Johnson & Johnson Announces Second $2 Billion Manufacturing Facility in North Carolina
3
Agenus Closes $141 Million Immunotherapy Collaboration with Zydus Lifesciences
4
Why Biotech’s Clinical Maturity Is Driving New Partnerships and Capacity Plays
5